AARD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

AARD ▼ -0.66% at T+5d

SHORT call ✓ call won +0.66% · α vs SPY +1.62% · entry $4.57 → $4.54

Next anchor: T+20d in 2d

Last close $3.59 (close Jun 8) · +21.44% from $4.57 entry (call sign-flipped)

Entry anchored
May 14, 03:59 PM ET
via Databento tick

T+1d

-4.60%

call +4.60% · α +4.53%

$4.36

settled 26d ago

T+5d

-0.66%

call +0.66% · α +1.62%

$4.54

settled 20d ago

T+20d

—

call — · α —

—

in 2d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Aardvark Therapeutics announced the FDA placed a full clinical hold on its IND for ARD-101, covering the Phase 3 HERO trial and open-label extension in Prader-Willi Syndrome. The company will unblind accumulated data to assess next steps, while holding $91.2M in cash to fund operations into mid-2027. This is a severe setback for a clinical-stage biotech with ARD-101 as its sole pipeline asset.

Actionable Insight

The clinical hold removes near-term upside catalysts for AARD. Monitor for FDA feedback and unblinded data readout — if data is negative, the stock could face further downside. Cash runway into mid-2027 provides some time but no revenue floor. Traders should expect high volatility on any regulatory or data updates.

Key Facts

FDA placed a full clinical hold on ARD-101 IND, covering all ongoing studies including Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).
Clinical hold follows a previously announced voluntary pause; no timeline for resolution provided.
Aardvark intends to unblind HERO and OLE trial data to evaluate efficacy and safety for next steps.
As of March 31, 2026, cash and equivalents totaled $91.2M, sufficient into mid-2027.
68 patients dosed in HERO trial and 19 in OLE trial as of February 27, 2026.

Financial Impact

Full clinical hold on sole pipeline asset (ARD-101) for PWS; $91.2M cash runway into mid-2027 provides limited buffer but no near-term revenue catalyst.

pipelinecash runwayregulatory risk

Risk Factors

Full clinical hold may require additional clinical data or trial redesign before lifting, delaying program by years.
Unblinded data could reveal safety or efficacy concerns that permanently end the ARD-101 program.
With ARD-101 as the only pipeline asset, a program termination would leave Aardvark with no clinical-stage candidates.
Cash burn without revenue could necessitate dilutive financing if hold persists beyond mid-2027.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

72% bullish (18 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295315

7 reports for AARD

T+1T+5T+20T+60

100% Hit rate 5 of 5 directional calls best @ T+20▲ +31.96%May 7, 2026

Filters

Reports for AARD — sortable, filterable
	Type				Now
May 14, 2026 26d ago	Press Release BEARISH ★ 8/10	$4.57 $4.54	▲ +0.66%	▲ +1.62%	$3.59 (+21.44%)
May 7, 2026 4w ago	8-K BEARISH ★ 6/10	$5.60 $6.59	▼ −17.68%	▼ −16.17%	$3.59 (+35.89%)
Apr 6, 2026 9w ago	EFFECT BEARISH ★ 7/10	$4.13 $4.01	▲ +2.91%	▲ +7.04%	$3.59 (+13.08%)
Apr 3, 2026 9w ago	424B5 BEARISH ★ 7/10	$4.13 $4.01	▲ +2.91%	▲ +7.04%	$3.59 (+13.08%)
Mar 24, 2026 11w ago	8-K NEUTRAL ★ 4/10	$3.77 $3.77	· 0.00%	▲ +0.42%	$3.59 (−4.77%)
Mar 23, 2026 11w ago	S-3 BEARISH ★ 7/10	$3.77 $3.77	· 0.00%	▼ −0.42%	$3.59 (+4.77%)
Mar 23, 2026 11w ago	Press Release BEARISH ★ 8/10	$3.77 $3.77	· 0.00%	▼ −0.42%	$3.59 (+4.77%)

US Market Status

Market Closed — Opens in 8h 13m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access